HQY vs. ENSG, JAZZ, MASI, RVMD, ITCI, VKTX, BPMC, ASND, EXEL, and CYTK
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include The Ensign Group (ENSG), Jazz Pharmaceuticals (JAZZ), Masimo (MASI), Revolution Medicines (RVMD), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
The Ensign Group (NASDAQ:ENSG) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.
The Ensign Group currently has a consensus target price of $124.60, suggesting a potential upside of 4.77%. HealthEquity has a consensus target price of $96.17, suggesting a potential upside of 21.44%. Given The Ensign Group's stronger consensus rating and higher possible upside, analysts clearly believe HealthEquity is more favorable than The Ensign Group.
HealthEquity received 160 more outperform votes than The Ensign Group when rated by MarketBeat users. Likewise, 69.24% of users gave HealthEquity an outperform vote while only 66.10% of users gave The Ensign Group an outperform vote.
96.1% of The Ensign Group shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 3.9% of The Ensign Group shares are held by insiders. Comparatively, 2.2% of HealthEquity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, HealthEquity had 2 more articles in the media than The Ensign Group. MarketBeat recorded 9 mentions for HealthEquity and 7 mentions for The Ensign Group. The Ensign Group's average media sentiment score of 1.24 beat HealthEquity's score of 1.20 indicating that HealthEquity is being referred to more favorably in the news media.
The Ensign Group has a net margin of 5.67% compared to The Ensign Group's net margin of 5.57%. HealthEquity's return on equity of 17.60% beat The Ensign Group's return on equity.
The Ensign Group has higher revenue and earnings than HealthEquity. The Ensign Group is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
The Ensign Group has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Summary
HealthEquity beats The Ensign Group on 10 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
